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Geospatiotemporal and causal inference study of
cannabis and other drugs as risk factors for female
breast cancer USA 2003–2017
Albert Stuart Reece1,2,* and Gary Kenneth Hulse1,2

Abstract
Breast cancer (BC) is the commonest human cancer and its incidence (BC incidence, BCI) is rising worldwide. Whilst both tobacco
and alcohol have been linked to BCI genotoxic cannabinoids have not been investigated. Age-adjusted state-based BCI 2003–2017 was
taken from the Surveillance Epidemiology and End Results database of the Centers for Disease Control. Drug use from the National
Survey of Drug Use and Health, response rate 74.1%. Median age, median household income and ethnicity were from US census.
Inverse probability weighted (ipw) multivariable regression conducted in R. In bivariate analysis BCI was shown to be significantly
linked with rising cannabis exposure {β-est. = 3.93 [95% confidence interval 2.99, 4.87], P = 1.10 × 10−15 }. At 8 years lag cigarettes:cannabis
[β-est. = 2660 (2150.4, 3169.3), P = 4.60 × 10−22 ] and cannabis:alcoholism [β-est. = 7010 (5461.6, 8558.4), P = 1.80 × 10−17 ] were significant
in ipw-panel regression. Terms including cannabidiol [CBD; β-est. = 16.16 (0.39, 31.93), P = 0.446] and cannabigerol [CBG; β-est. = 6.23
(2.06, 10.39), P = 0.0034] were significant in spatiotemporal models lagged 1:2 years, respectively. Cannabis-liberal paradigms had higher
BCI [67.50 ± 0.26 v. 65.19 ± 0.21/100 000 (mean ± SEM), P = 1.87 × 10−11 ; β-est. = 2.31 (1.65, 2.96), P = 9.09 × 10−12 ]. 55/58 expected values
>1.25 and 13/58 >100. Abortion was independently and causally significant in space–time models. Data show that exposure to cannabis
and the cannabinoids ∆9-tetrahydrocannabinol, CBD, CBG and alcoholism fulfil quantitative causal criteria for BCI across space and
time. Findings are robust to adjustment for age and several known sociodemographic, socio-economic and hormonal risk factors and
establish cannabinoids as an additional risk factor class for breast carcinogenesis. BCI is higher under cannabis-liberal legal paradigms.
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Introduction
Globally 2.1 million women were diagnosed with breast cancer
(BC) in 2018 including 626 679 deaths from this cause [1]. This
equates to one case every 18 seconds. The BC incidence (BCI) is
increasing worldwide. In the USA 279 100 cases are expected to
occur in 2020 which makes BC the commonest solid organ cancer
in the USA and comprising 15.5% of the 1 806 590 visceral cancers
expected in 2020 [2]. 276 480 of these tumours or 99.06% occur in
females [2] and female BC will be the subject of analysis. Data
from the Centers of Disease Control (CDC) Atlanta, Georgia, indicate that the BCI rose nationally from about 100 cases/100 000
to 127 cases/100 000 from 1980 to 1987, possibly related to the
widespread introduction of mammographic screening but has
been essentially unchanged since that time [2]. Happily the mortality rate has dropped progressively since 1990 due to various
screening practices enabling earlier detection and therapeutic
advances [2].

The aetiology of BC is usually understood to relate to a combination of factors including increased hormonal exposure so that
factors such as early menarche, delayed menopause, reduced
parity, advanced maternal age at first pregnancy, reduced breastfeeding, oral contraception and menopausal hormone replacement therapy are known to be linked with increased BCI [1, 3–6].
Obesity, central adiposity, lack of physical activity and alcohol
use are also implicated [1]. The role of tobacco is controversial,
although some data indicate it may increase severity of BC in those
identified. The literature on the effects of elective termination
of pregnancy on BC is controversial with meta-analyses reaching
both positive [7] and negative conclusions [8, 9] being published.
The main factors that influence risk include being a woman and
getting older with most BC found in women who are 50 years old
or older, with age also likely reflecting exposure to environmental factors. Significant ethnic differences are also described [10].
Mutations in the BRCA genes on Chromosomes 17 and 13 which
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Methods
Data

Drugs
Drug use data at the state level was taken from the statebased datafiles of the National Survey of Drug Use and Health
(NSDUH) Restricted Use Data Analysis System (RDAS) of the Substance Abuse and Mental Health Data Archive (SAMHDA) conducted annually by the Substance Abuse and Mental Health Services Administration (SAMHSA) [50]. The drugs of interest were
tobacco (as last month cigarettes use, shown as “Cigarettes”
in tables); alcohol use disorder (“AUD”; formerly known as
alcohol dependence); last month cannabis use (“Cannabis”);
last year non-medical use of analgesics (“Analgesics”) and last
year use of cocaine (“Cocaine”). Cannabis use intensity by
ethnicity at the national level was also sourced from the
SAMHSA NSDUH RDAS data set using the RDAS variable “mrjmdays”. The concentration of cannabinoids in federal seizures
was taken from publications of the Drug Enforcement Agency
[51–53].

Socio-Economic
Data on state-based ethnicity prevalence, median household
income (“Income” in the tables) and median age was taken
from the US Census Bureau via the tidycensus package in
R [54]. The ethnicities of interest were Caucasian-American,
African-American, Hispanic-American, American Indian/Alaska
Native (AIAN) and Native Hawaiian/Pacific Islander (NHPI).
Some of the CDC data refers to Non-Hispanic ethnicities (NH).
This abbreviation appears in our tables where appropriate. In
some cases there were minor disparities between the ethnic
designations employed from the major data sets. Ethnicities
were matched as closely as possible between the various data
sets.

Reproductive Factors
Data on termination of pregnancy were sourced from the Annual
CDC Abortion Surveillance Monitoring Reports and was recorded
for abortions performed for intrastate residents only [55]. Data
on menopausal hormone replacement therapy (HRT) was sourced
by specific enquiry from CDC (Atlanta, Georgia). Following the
Womens Health Initiative Study [3] a marked decline occurred
in the rate of HRT prescribing nationally [56]. CDC was able
to provide national-level data only for five years as discussed
below [56]. Data were temporally kriged to provide estimates
for the intervening years. As mentioned, only national-level
data were available. Data on hormonal methods of contraception (hormonal contraception/combined oral contraceptive pill,
COCP) were sourced from published reports directed by specific
enquiry from CDC [56–60]. Hormonal methods of contraception
include the sum of oral contraception, injectable contraception
and implant contraception. Data were only supplied for four years.
The data set was completed for the intervening years by temporal
kriging.

Cannabis Legal Status
Cannabis legal status was derived from an internet search [61].

Cancer

Derived Data

National age-adjusted BCI rates including ethnic-specific incidence rates were taken from the SEER*Explorer online web tool
[10]. State-based age-adjusted BCI data were taken from the
National Program of Cancer Registries (NPCR) and Surveillance,
Epidemiology, and End Results (SEER) Incidence data set US Cancer Statistics Public Use database 2019 submission 2001–2017 for
each US state using the SEER*Stat software rate sessions [49].

State-Based Cannabinoid Exposure Estimates
State-based estimates of cannabinoid exposure were derived by
multiplying the concentration of cannabinoids identified in federal seizures of cannabis as published by DEA laboratories [51–53]
by the mean level of last month cannabis use in that state following accepted practices [16, 43, 62–69]. The cannabis use intensity
in each category of use (1–3 days last month, 4–5 days, 6–19 days
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play critical roles in homologous DNA repair are linked with BC.
BRCA mutations occur with varying frequencies by ethnicity being
0.5% amongst Asian populations and 10.2% amongst women of
Ashkenazi Jewish descent [1]. Mutations in checkpoint 2 kinase
(CHEK2), ataxia telangiectasia mutated (ATM), partner and localizer of BRCA2 (PALB2), tumour protein P53 (TP53), phosphatase
and tensin homolog (PTEN) and serine threonine kinase 11 (STK11)
are also implicated [1].
A recent PubMed literature search identified numerous papers
discussing the putative potential of cannabinoid-derived therapeutics in BC for various indications albeit in the absence of supportive randomized clinical trials [11], however we were not able to
identify any papers investigating the possibility that cannabinoids
may impact the aetiological risk for BCI.
On the basis of several published series [12–16] it is often said
that the cancer which is most closely linked with cannabis exposure is testicular cancer [17–21]. Other studies link adult cannabis
exposure with cancer of the head and neck, larynx, prostate, lung,
brain and urothelium [12, 22–31] and for several tumours dose–
response relationships have been demonstrated [22, 24, 25, 32].
However it is important to appreciate that the evidence linking cannabis exposure with a paediatric cancer whose incidence peaks in the first 5 years of life—acute myeloid leukaemia
(AML) [33–35] is equally as strong as that for testicular cancer [33, 34, 36, 37]. Cannabis has also been linked with other
paediatric tumours including neuroblastoma, rhabdomyoblastoma, acute lymphoid leukaemia (ALL) and total paediatric cancer
[28, 33, 34, 36, 38–43]. It is widely understood that paediatric cancer largely results from inherited genotoxic or epigenotoxic carcinogenic insults [44–46]. Indeed, as was found by the California
Environmental Protection Agency some years ago the evidence for
paediatric cancerogenesis is more uniform than the evidence for
adult oncogenesis [47].
Since BC (present report and [37]) is the commonest adult cancer and ALL, along with total paediatric cancer, is the commonest
paediatric cancer these findings make cannabis a major player in
the epidemiology of both adult and childhood oncogenesis and
therefore across the whole span of life. Since cannabis has been
shown to be driving ALL and total paediatric cancer rates [43, 48]
transgenerational aspects of cannabinoid oncogenesis are clearly
significant. In that the breast is also part of the reproductive system it is clearly important to investigate the possible involvement
of cannabis and cannabinoids in breast tumourigenesis.
This study set out to investigate the potential involvement of
cannabis, cannabinoids and other substances in patterns of BCI
across space and time in the USA to assess if any epidemiological
relationship could be identified, if any putative relationship was
robust to multivariable adjustment and if the relationship fulfilled
the formal criteria for causality.
Our intention prior to data analysis was to include substance
exposure as an addition to known covariates which had previously
been linked with BCI.

Cannabinoid and other drug risk factors for female breast cancer
and 20–30 days) was summed and averaged for each year of the
NSDUH for each ethnicity to provide a cannabis use intensity
score. This score was then multiplied by the prevalence of the relevant ethnicity in that state to derive a state-based estimate of
monthly cannabis exposure. This measure was then multiplied by
the ∆9–tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations, respectively, in federal seizures to derive estimates
of ethnic THC and CBD exposures at the state level.

Substance Exposure Quintiles
Substance exposure in each year was divided into quintiles for the
substances cigarettes, AUD, cannabis, cocaine and analgesics.

Substance exposure quintiles were dichotomized as the two highest quintiles versus the lower three quintiles. Similarly cannabis
legal status was dichotomized as states where cannabis was illegal
versus those where a more liberal policy was in place.

Statistics
Data were processed in R version 4.0.3 and R-Studio version
1.3.1093 from the R Foundation for Statistical Computing and
the Comprehensive “R” Archive Network (CRAN) in November
2020. Numeric data are listed as mean ± SEM. Data were manipulated using dplyr and the tidyverse suite [70]. All data was
log-transformed based on the results of the Shapiro test. The
probability of Student’s t and Fisher’s F at extreme values was
calculated using the functions pt and pf from the stats package.
Graphs were drawn in ggplot2 [71]. Maps were drawn with ggplot2
and sf (“Simple Features”) [71, 72]. All maps have been originally
drawn for this paper. Some maps use the “plasma” colour palette
from R package viridis [73]. Other colour palettes were custom
designed for this paper. Reduction of initial regression models
was by serial deletion of the least significant term according to
the classical method of model reduction. Only final reduced models are presented. Serial linear models were processed in broom,
broom.mixed and purrr [74–76].
Correlation matrices were constructed using the R-packages
corrplot and corrgram [77–79]. Paired correlation plots were constructed with the ggpairs function from GGally [80]. Graphs were
assembled into four or six panels using the ggarrange function
from ggpubr [81].
A variety of regression techniques were used for the following reasons. Linear regression was performed in R-Base. Mixed
effects regression from package nlme [82, 83] was performed
as it is ideally suited to repeated measures of the same locations and it provides standard deviations from which to calculate
expected values (e-values), and inverse probability weights can be
employed. However, it does not allow lagging or the use of instrumental variables. Panel regression from package plm [84] was
performed as the data are of the panel form and it allows the use
of instrumental variables and lagging, although not together; and
inverse probability weights can be employed. It also provides standard deviations from which e-values can be calculated. Robust
generalized regression was performed from the survey package
[81] as it allows inverse probability weights to be employed and
provides robust regression estimates. It does not however allow
lagging, instrumental variables or provide standard deviations
for the calculation of e-values. Geospatiotemporal regression was
performed using the spatial panel random error maximum likelihood (spreml) function from package splm (spatial panel linear
models) [85–87] as the data are distributed across time and space,
which are shown to be important environmental factors in these

regression models, both spatial and temporal lagging can be performed, and standard deviations can be calculated to allow the
derivation of e-values. However, models cannot be weighted using
inverse probability weights and instrumental variables cannot be
employed.
For both mixed effects and robust generalized regression the
state was the level of the identifier.
For panel models the effects were two ways which relate to
both space and time, model type was pooling relating to least
squares algorithm, the random method was that of Swarmy and
the instrumental method that of Amemiya [84]. All panel models
were inverse probability weighted.
Geospatial neighbourhood weights using the “queen” edge and
corner relationships were calculated and edited using the spdep
package in R [88]. All geospatial models used the spatial error
with serial correlation and random effects with spatial lagging
(“semsrre+lag”) error structure which was confirmed in final models to be the appropriate model design specification as previously
described [89]. Model coefficients are presented as phi for the
random error component, psi for the serial correlation in the residual error, rho for the spatial error coefficient and lambda for the
autocorrelation in the spatial error. The spreml constrained optimization method used was that of Baltagi, Pfaffermayr, Greene
and Song (“BFGS”) [87, 89].
The use of inverse probability weights allows an observational
study to be considered as a pseudo-randomized study from which
causal conclusions can be drawn. Inverse probability weights
were calculated using the R package ipw [90]. Cannabis exposure was adjusted across groups controlled for all other substance exposure. Inverse probability weighting was applied to all
robust generalized regression models, mixed effects models and
panel models. e-Values are a quantitative index of the required
association between some hypothetical unmeasured confounding
variable and both the dependent variable and the exposure of concern, measured on the risk ratio scale. e-Values were calculated
from the R package EValue [91–93]. e-Values greater than 1.25
are considered in the literature to be indicative of presumptively
causal relationships [94].
All t-tests were two tailed. P < 0.05 was considered significant
throughout.

Data Availability
All data used during this study including datafiles, shapefiles,
edited geospatial weights, inverse probability weights and programming code in “R” are included in this published article
and its supplementary information files. Data have been made
publicly available on the Mendeley Database Repository and can
be accessed via: http://dx.doi.org/10.17632/yzjcvhphmc.1.

Ethics
The Human Research Ethics Committee of the University of Western Australia provided ethical approval for the study to be undertaken on 7 January 2020 (No. RA/4/20/4724). Consent to participate
was not required as the data utilized were derived from publicly
available anonymous data sets and no individually identifiable
data were employed.

Results
The BC data set was the national BC state-based census data set
[49]. The NSUDH is an annually conducted nationally representative data set which is representative of the non-institutionalized
US population. It has a published 74.1% response rate [95].
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Figure 1: Graphs of relationship of BCI to substance exposure

Supplementary Figure S1 map-graphically presents the rates
BCI across the USA over time.
As the leading risk factor for BC is chronological age it is important to take that into account. Supplementary Figure S2 mapgraphically presents the relative median population ages across
the USA over time.
Supplementary Figure S3 standardizes the BCI by age by dividing the BCI by chronological age. The results are presented
map-graphically and considerable changes are noted from Supplementary Figure S1 with the hotspot in New England becoming
more moderate and Utah emerging as a high corrected-incidence
zone.
Supplementary Table S1A shows the raw data for menopausal
HRT as derived from CDC data [56]. Supplementary Table S1B
shows temporal kriging of these data to complete the missing
years of the analysis. This is required as spatiotemporal analysis algorithms do not permit the presence of missing data. As
no state-based data were available for this parameter the same
values have been used for all states.
Supplementary Table S2 shows the data for the rates of hormonal contraception used in each US state as directed by CDC
[57–60].
Supplementary Table S3 shows these data after temporal kriging for each of the years 2003–2017 and completion of the data set
for each state.
Supplementary Table S4 shows the elective termination of
pregnancy (abortion) data as derived from the annual CDC Abortion surveillance reports [55]. Supplementary Table S5 shows
these data after temporal kriging.

Supplementary Table S6 shows the final bivariate linear regression results of the BCI against various groups of covariates. Significant relationships with cannabis use, cannabinoids and abortion
rates are noted.
Supplementary Figure S4 shows the relationship of the (A)
BCI to the abortion rate, (B) the log(BCI) to the standardized
(z-transformed) abortion rate, (C) the log(BCI) to the log abortion
rate and (D) the log(BCI) to the log (standardized abortion rate).
The positive relationship between the BCI and abortion rate is
noted to hold regardless of the transformation of both variables.
Supplementary Table S7 gives the final bivariate linear regression models for the BCI against the logarithm of the abortion rate.
The relationship is noted to be highly significant.
Supplementary Table S6 lists the applicable linear regression results for the BCI by ethnicity for the state-level data. In
the first model of the table the comparator group is AfricanAmericans. In the model section of the table the comparator group
is AIAN-Americans. In each case highly significant differences are
noted.
Figure 1 shows the BCI as a function of exposure to various substances. Obviously positive relationships are shown with cannabis
and cocaine.
Figure 2 shows the BCI as a function of various cannabinoid
exposures. Positive relationships are noted in each case.
Supplementary Table S8 gives the line slopes of the regression
lines for the various substances and the various cannabinoids.
Since the rates of cigarette use, alcohol dependence, cocaine
and analgesic use and CBD exposure are all falling it is of interest
to consider quintile analyses of these exposures. Figure 3 shows
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Figure 2: Graphs of relationship of BCI to cannabinoid exposure
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Figure 3: Graphs of relationship of BCI to substance exposure quintiles. (A) Scatterplot of BCI by cigarette use quintiles over time, (B) scatterplot of BCI
by AUD quintiles over time, (C) scatterplot of BCI by cannabis use quintiles over time, (D) boxplot of BCI by cigarette use quintiles over aggregated
time, (E) boxplot of BCI by AUD quintiles over aggregated time and (F) boxplot of BCI by cannabis use quintiles over aggregated time

the BCI as a function of the tobacco, AUD and cannabis quintiles
as scatterplots and boxplots. Chi-squared test for trend for each
of these three substances is: tobacco: Chi.Squ. = −892.39, df = 796,
P = 0.0096; AUD: Chi.Squ. = 814.31, df = 796, P = 0.3184; cannabis:
Chi.Squ. = 853.62, df = 796, P = 0.767.

Supplementary Table S9 illustrates the results of these regressions for four substances by quintile.
The applicable slopes, regression coefficients and significance
values of the bivariate linear regressions for the cannabis quintiles are shown in Supplementary Table S10. The lower half of
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Figure 4: Graphs of relationship of BCI to dichotomized cannabis exposure quintiles. (A) scatterplot and (B) boxplot

the table lists the results for consideration of the dichotomized
quintile comparisons. Highly significant results are shown.
The cannabis quintiles may be further aggregated into the
lower three quintiles compared to the upper two quintiles. The
time-based trends and boxplots for BCI are shown in Fig. 4. The
differences between the BCIs of the higher and lower quintiles are
significant (68.45 ± 0.36 v. 65.62 ± 0.18, t = 6.9603, df = 232.24 and
P = 3.44 × 10−11 ). The BCI of the fourth cannabis quintile is significantly lower than that of the fifth cannabis quintile (66.54 ± 0.45
v. 68.45 ± 0.36, t = 3.133, df = 279.96, P = 0.0010).
Figure 5 is a compound correlogram prepared in the R package “corrplot”. It shows the correlations colour coded in the lower
triangle and with the significance of the Pearson correlation coefficients shown in the upper triangle both by their P-value and as
ellipses. The correlations are coded from purple to red in increasing order. Ellipses slope positively for positive correlations and

negatively for negative correlations. The width of the ellipse also
codes the strength of association with narrower ellipses indicating higher correlations. The diagonal is blank. The correlogram
is ordered by hierarchical clustering according to the Ward 2
method. The BCI is denoted as “CancerRt” in this figure. Positive
relationships amongst the cannabinoids and across ethnic THC
exposure are noted in this correlogram. The BCI is noted to be positively related to cannabis, cannabinoids including CBD, abortions
and cocaine exposure.
Supplementary Table S11 lists the results of mixed effects
repeated measures regressions with state as the identifying variable from a series of successively more complex (mostly) additive
models. The model series is of interest because in each model in
which cannabis appears it is seen to be significant.
Supplementary Table S12 lists a series of successively more
complex interactive mixed models. The first model is the full
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interactive model and includes age, substances, ethnic prevalences, income and reproductive exposures. Five terms including
cannabis are significant, and cannabis is noted to be independently and powerfully significant in this model {β-est. = 24.73
[95% confidence interval (CI) 14.98, 34.47], P = 8.40 × 10−7 }. In
place of the ethnic prevalence the second and third models list
the ethic THC and CBD exposure, respectively. In the second
model Asian THC exposure is noted to be significant [β-est. = 3.53
(2.88, 4.18), P = 1.10 × 10−24 ] and in the third model Caucasian
CBD exposure is noted to be significant [β-est. = 65.45 (50.11,
80.79), P = 3.00 × 10−16 ]. The fourth model features the individual
cannabinoids as main effects. CBD, cannabigerol (CBG) and THC
are all independently significant of which the most positively significant one is CBD [β-est. = 3.00 (0.53, 5.47), P = 0.0174]. Terms
including cannabinoids are significant [β-est. = 150.10 (74.14,
226.05), P = 0.0001].
The intrastate elective pregnancy termination rate is also noted
to be highly significant in all four models.
Supplementary Table S13 shows the final regression models
from panel regression first including age and substances, then
a full additive model and then a full interactive model. In each
model cannabis is significant [from β-est. = 26.87 (22.81, 30.94),
P = 1.06 × 10−34 ].
Supplementary Table S14 shows the results from final interactive panel models lagged to 2, 4, 6 and 8 years. In each
case terms including cannabis are noted to be significant [from
β-est. = 1016.82 (822.42, 1211.21), P = 1.30 × 10−22 at 6 years lag].
Supplementary Table S15 lists a series of final interactive
panel models which include respectively cannabinoids, ethnic
THC exposure and ethnic CBD exposure as instrumental variables. Interestingly in these models the significance of cannabis

in the model covariates is greatly reduced. In the final model
where ethnic CBD exposure is listed as the instrumental variable no terms including cannabis appear. These results confirm
that the effect of cannabis as a covariate is partly accounted
for by the listing of the various cannabinoids as instrumental
variables.
Table 1 presents a series of geospatiotemporal models of
increasing complexity. As shown in the first model when age
and cannabis exposure are regressed interactively against the
BCI together only cannabis use remains significant in the final
model. The second model shows that when age and substances
are regressed additively against BCI the only term remaining in
the final model is cannabis exposure. The third model is an important additive model which lists all the non-ethnicity covariates.
Only cannabis exposure [β-est. = 1.56 (0.69, 2.42), P = 0.0004] and
abortion [β-est. = 1.20 (0.54, 1.85), P = 0.0003] remain as significant in the final model with positive coefficients. In a similar
interactive model terms including cannabis are highly significant
(fourth model). In a full interactive model including substance,
age, income and ethnicity terms including cannabis do not appear
in the final model (fifth model). In a full interactive model where
an interactive term between THC:CBD:CBG replaces the term for
cannabis an interactive term including the CBG:CBD interaction is
significant in the final model (sixth model).
In an interactive model which replaces ethnicity with ethnic THC exposure Non-Hispanic African-American, HispanicAmerican and Non-Hispanic Caucasian-American THC exposures
are significant in the final model (seventh model). When the ethnic CBD exposure is used to replace the ethnic prevalences the
CBD of the same three ethnic groups remains significant in the
final model (eighth model).

Downloaded from https://academic.oup.com/eep/article/8/1/dvac006/6539905 by guest on 31 May 2022

Figure 5: Corrplot correlogram of selected covariates of BCI (“CancerRt”). Lower triangle shows the numeric Pearson correlation coefficients
themselves colour coded and also with colour coding of the squares. The upper triangle shows the numeric P-values associated with these
correlations inside colour-coded ellipses. Ellipse sloping top the right indicate positive correlations and ellipses sloping to the left signify negative
correlations. The width of the ellipse also codes the strength of the relationship
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Table 1: Introductory geospatiotemporal models
Parameter

Estimate (CI)

P-value

SD

Log.Lik

Coefficient

Value

P-value

0.0007

3.6514

−1780.87

phi
psi
rho
lambda

1.5969
0.3437
−0.4217
0.4754

2.11E − 05
1.46E − 15
3.90E − 05
4.75E − 12

Additive model
spreml(Cancer_Rate ∼ Age + Cigarettes + Cannabis + AUD + Analgesics + Cocaine)
Cannabis
1.45 (0.61 2.29)
0.0007
3.6514

−1780.87

phi
psi
rho
lambda

1.5969
0.3437
−0.4217
0.4754

2.11E − 05
1.46E − 15
3.90E − 05
4.75E − 12

Cannabis alone
spreml(Cancer_Rate ∼ Age × Cannabis)
Cannabis
1.45 (0.61 2.29)

Interactive full model—Cannabinoids as main effects
spreml(Cancer_Rate ∼ Age + Cigarettes × THC × CBG × CBD +AUD + Analgesics + Cocaine + Income + Abortion + HRT + COCP + Caucas + African + Hispanic
+ Asian)
Abortion
1.21 (0.54 1.88)
0.0004
0.3096
−1763.67
phi
1.1775
4.41E − 05
Asian
1.26 (0.29 2.24)
0.0106
psi
0.3321
1.18E − 14
HRT
0.6 (0.06 1.13)
0.0279
rho
−0.4176
3.99E − 05
Caucas
4.69 (0.14 9.25)
0.0436
lambda
0.4478
5.27E − 11
Cigarettes:CBG:CBD
−0.65 (−1.19 −0.11)
0.0180
COCP
−0.09 (−0.15 −0.02)
0.0081
AIAN
−26.2 (−45.33 −7.07)
0.0073
Interactive full model—Ethnic THC exposure as main effects
spreml(Cancer_Rate ∼ Age + Cigarettes × AUD + Analgesics + Cocaine + Income + Abortion + HRT + COCP + Caucas_THC × African_THC × Hispanic_THC
+ Asian_THC)
Abortion
1.3 (0.63 1.96)
0.0001
3.5743
−1764.30
phi
1.5874
7.72E − 06
NHAfrican_THC:Hispanic_THC
1.14 (0.48 1.81)
0.0007
psi
0.3168
2.17E − 13
NHAfrican_THC
1.8 (0.34 3.25)
0.0157
rho
−0.4297
1.26E − 05
Hispanic_THC
−2.41 (−3.81 −1.02)
0.0007
lambda
0.4419
6.98E − 11
NHCaucas_THC:Hispanic_THC
−1.5 (−2.2 −0.81)
2.41E − 05
Interactive full model—Ethnic CBD exposure as main effects
spreml(Cancer_Rate ∼ Age + Cigarettes × AUD + Analgesics + Cocaine + Income + Abortion + HRT + COCP + Caucas_CBD × African_CBD × Hispanic_CBD
+ Asian_CBD)
NHCaucas_CBD
5.63 (2.85, 8.4)
7.05E − 05
3.4942
−1759.431
phi
1.4579
9.55E − 05
Abortions
1.09 (0.43, 1.76)
0.0013
psi
0.3004
8.16E − 12
Income
3.11 (1.12, 5.11)
0.0022
rho
−0.3859
3.00E − 04
Age
0.35 (0.11, 0.6)
0.0050
lambda
0.4104
2.94E − 08
Analgesics
45.52 (10.58, 80.45)
0.0107
COCP
−0.08 (−0.15, −0.02)
1.21E − 02
NHAfrican_CBD:Hispanic_CBD
−0.67 (−1.19, −0.15)
0.0112
Hispanic_CBD
−6.03 (−9.76, −2.31)
0.0015
NHAfrican_CBD
−7.62 (−11.59, −3.64) 0.0002
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Additive model without ethnicity
spreml(Cancer_Rate ∼ Age + Cigarettes × Cannabis × AUD + Analgesics + Cocaine + Income + Abortion + HRT + COCP)
Abortion
1.2 (0.54, 1.85)
0.0003
3.5943
−1772.073
phi
1.575016
5.22E − 05
Cannabis
1.56 (0.69, 2.42)
0.0004
psi
0.329217
1.73E − 14
COCP
−0.09 (−0.15, −0.03)
0.0040
rho
−0.424822
2.90E − 05
lambda
0.469234
4.99E − 12
Interactive model
spreml(Cancer_Rate ∼ Age + Cigarettes × Cannabis × AUD + Analgesics + Cocaine)
Cigarettes:Cannabis
3.59 (1.94 5.24)
1.90E − 05
3.6773
−1777.73
phi
1.6995
8.95E − 06
Analgesics
42.62 (9.22 76.02)
0.0124
psi
0.3144
5.52E − 13
rho
−0.4492
4.54E − 06
lambda
0.4883
4.77E − 14
Interactive full model
spreml(Cancer_Rate ∼ Age + Cigarettes × Cannabis × AUD + Analgesics + Cocaine + Income + Abortion + HRT + COCP + Caucas + African + AIAN + Hispanic
+ Asian)
Asian
2 (1.08 2.92)
2.22E − 05
3.3370
−1763.77
phi
1.2367
5.59E − 05
Abortion
1.07 (0.43 1.71)
0.0010
psi
0.3152
3.41E − 13
Analgesics
33.66 (1.66 65.66)
0.0393
rho
−0.4243
2.38E − 05
Hispanic
−1.19 (−2.17 −0.21)
0.0174
lambda
0.4645
2.30E − 12
COCP
−0.08 (−0.14 −0.02)
0.0090
AIAN
−26.75 (−46.04 −7.46) 0.0066
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Table 2: Lagged geospatiotemporal models
Lagged variables

Cannabis

Cannabis

Cannabis

Cannabis

Cannabis

Estimate (CI)

P-value

SD

Log.Lik

Coefficient

Value

P-value

Lagged models
Temporal lags
0 Lags
spreml(Cancer_Rate ∼ Age + Cigarettes × Cannabis × AUD + Analgesics + Cocaine + Income + Abortion + HRT + COCP)
Abortion
1.15 (0.49 1.81)
0.0006
3.6050 −1773.49 phi
1.6236
Cigarettes:Analgesics
164.45 (24.58 304.33)
0.0212
psi
0.3094
Cannabis:AUD
7.26 (0.83 13.7)
0.0270
rho
−0.4524
Cigarettes
−14.67 (−26.72 −2.62)
0.0170
lambda
0.4933

8.52E − 06
1.78E − 12
3.72E − 06
1.19E − 14

1 Lag
spreml(Cancer_Rate ∼ Age + Cigarettes × Cannabis × AUD + Analgesics + Cocaine + Income + Abortion + HRT + COCP)
Cigarettes:Cannabis:Analgesics
313.25 (200.08 426.42) 5.79E − 08 3.6567 −1644.44 phi
1.8471
Cigarettes:Analgesics
560.57 (258.27 862.87) 0.0003
psi
0.3018
Abortion
1 (0.28 1.72)
0.0065
rho
−0.4902
Cannabis:Analgesics
−42.22 (−65.32 −19.13) 0.0003
lambda
0.4833

9.66E − 06
8.13E − 12
6.15E − 07
5.97E − 14

2 Lags
spreml(Cancer_Rate ∼ Age + Cigarettes × Cannabis × AUD + Analgesics + Cocaine + Income + Abortion + HRT + COCP)
Abortions
1.12 (0.36, 1.88)
0.0040
3.5116 −1528.31 phi
1.4823
Income
3.63 (0.75, 6.51)
0.0136
psi
0.3170
Cigarettes:Cannabis
21.23 (3.72, 38.73)
0.0175
rho
−0.3503
Cigarettes
54.13 (6.97, 101.3)
0.0245
lambda
0.4109
Age
0.28 (0, 0.57)
0.0487
Cannabis
−5.17 (−9.28, −1.06)
0.0137
3 Lags
spreml(Cancer_Rate ∼ Age + Cigarettes × Cannabis × AUD + Analgesics + Cocaine + Income + Abortion + HRT + COCP)
Abortion
0.94 (0.17 1.71)
0.0165
3.5863 −1415.30 phi
1.6770
Income
3.58 (0.6 6.57)
0.0184
psi
0.3215
Cigarettes:Cannabis
20.15 (1.77 38.54)
0.0316
rho
−0.4356
Cigarettes
51.38 (1.23 101.54)
0.0447
lambda
0.4696
Cannabis
−4.49 (−8.63 −0.37)
0.0328
4 Lags
spreml(Cancer_Rate ∼ Age + Cigarettes × Cannabis × AUD + Analgesics + Cocaine + Income + Abortion + HRT + COCP)
Income
3.84 (0.7 6.98)
0.0167
3.6311 −1295.27 phi
1.8627
Abortion
0.97 (0.12 1.83)
0.0257
psi
0.2750
Cigarettes
57.11 (4.05 110.18)
0.0349
rho
−0.4694
Cigarettes:Cannabis
20.84 (1.36 40.31)
0.0360
lambda
0.4716
Cannabis
−4.41 (−8.7 −0.11)
0.0442

5.39E − 05
1.04E − 11
0.0043
1.27E − 06

1.66E − 05
2.15E − 10
0.0001138
1.75E − 10

3.80E − 05
2.05E − 07
6.62E − 05
3.04E − 10

Spatial lags
1 Spatial lag
spreml(Cancer_Rate ∼ Age + Cigarettes × Cannabis × AUD + Analgesics + Cocaine + Income + Abortion + HRT + COCP + Caucas + African
+ AIAN + Hispanic + Asian)
Abortion
1.29 (0.62 1.95)
0.0002
3.3558 −1763.66 phi
1.2615
2.10E − 05
Cigarettes:Analgesics
7.59 (2.93 12.26)
0.0014
psi
0.3072
1.01E − 12
Asian
1.51 (0.48 2.54)
0.0041
rho
−0.4232 3.23E − 05
Cigarettes:AUD
261.75 (81.94 441.55)
0.0043
lambda
0.4559
1.62E − 11
Cannabis
20.69 (5.29 36.09)
0.0084
COCP
−0.08 (−0.15 −0.02)
0.0125
Hispanic
−1.44 (−2.44 −0.45)
0.0046
2 Spatial lags
spreml(Cancer_Rate ∼ Age + Cigarettes × Cannabis × AUD + Analgesics + Cocaine + Income + Abortion + HRT + COCP + Caucas + African
+ AIAN + Hispanic + Asian)
Asian
2.06 (1.05 3.07)
6.28E-05
3.1767 −1763.14 phi
0.9754
5.66E − 05
Abortion
1.19 (0.52 1.87)
0.0005
psi
0.3165
2.36E − 13
Cigarettes:Analgesics
4.4 (1.16 7.64)
0.0077
rho
−0.3874 0.0003155
HRT
0.77 (0.19 1.35)
0.0093
lambda
0.4393
1.25E − 09
Caucas
6.02 (1.34 10.7)
0.0117
African
0.57 (0 1.14)
0.0480
COCP
−0.08 (−0.15 −0.02)
0.0131
Hispanic
−1.27 (−2.21 −0.33)
0.0079
Lagging cannabinoids—THC × CBG
1 Temporal lag
(continued)
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Table 2: (Continued)
Lagged variables

THC
CBG

THC
CBG
CBD

Estimate (CI)

P-value

SD

Log.Lik

Coefficient

Value

spreml(Cancer_Rate ∼ Age + Cigarettes × THC × CBG × AUD + Analgesics + Cocaine + Income + Abortion + HRT + COCP
1.7257
+ Caucas + African + Hispanic + Asian)
phi
THC:AUD
16.69 (11.04 22.35)
7.33E-09 3.6471 −1644.66
psi
0.3180
Abortion
1.29 (0.54 2.04)
0.0007
rho
−0.4095
lambda
0.4269

P-value

9.95E − 06
6.87E − 13
0.0001757
2.15E − 08

Lagging cannabinoids—THC × CBG × CBD
1 Temporal lag
spreml(Cancer_Rate ∼ Age + Cigarettes × THC × CBG × CBD × AUD + Analgesics + Cocaine + Income + Abortion + HRT + COCP + Caucas
+ African + Hispanic + Asian)
Abortion
1.31 (0.54 2.08)
0.0009
3.7106 −1635.79
phi
1.9328
0.0001344
Cigarettes
67.68 (3.55 131.82)
0.0386
psi
0.2759
1.55E − 09
Cigarettes:CBD
16.16 (0.39 31.93)
0.0446
rho
−0.4358 3.65E − 05
CBD
−3.87 (−7.42 −0.31)
0.0329
lambda
0.4103
3.35E − 08
Cigarettes:THC CBD
−79.49 (−133.54 −25.43)
0.0039
Cigarettes:THC:CBG:CBD −21.85 (−36.69 −7.02)
0.0039
Cigarettes:THC
−294.66 (−492.99 −96.33) 0.0036
Cigarettes:THC CBG
−82.92 (−137.82 −28.01)
0.0031
Lagging cannabinoids—THC × CBG × CBD
2 Temporal lags
spreml(Cancer_Rate ∼ Age + Cigarettes × THC × CBG × CBD × AUD + Analgesics + Cocaine + Income + Abortion + HRT + COCP + Caucas
+ African + Hispanic + Asian)
Abortion
1.31 (0.54 2.07)
0.0008
3.7382 −1528.47
phi
1.8883
2.37E − 05
Cigarettes:CBG
0.0034
0.3182
1.22E − 11
6.23 (2.06 10.39)
psi
Cigarettes
26.11 (3.02 49.21)
0.0267
rho
−0.3918 0.000445
CBD
−0.8 (−1.57 −0.03)
0.0412
lambda
0.4254
4.61E − 08

One notes en passant that the intrastate abortion rate appears
as an independently significant term in all four models in which
it appears as an input term namely the last four of these models.
Table 2 presents a series of ten lagged geospatiotemporal models. Both spatially and temporally lagged models are presented.
The lagged variables are indicated in the first column. At temporal lags 1:4 terms including cannabis are significant in final
models and have positive regression coefficients (Models 1–5).
Cannabis exposure is independently significant at one spatial lag
[β-est. = 20.69 (5.29, 536.09), P = 0.0084; Model 6].
When an interactive term including the cannabinoids THC,
CBD and CBG is used to replace cannabis at one temporal lag
a term including CBD is significant [cigarettes:CBD interaction:
β-est. = 16.16 (0.39, 31.93), P = 0.0446]. When the same procedure
is repeated at two temporal lags terms including CBG and CBD are
significant in final models.
The intrastate abortion rate is again included in all ten final
models.
Table 3 lists selected e-values which issue from these models. Supplementary Table S16 is an ordered list of the minimal
e-values. It is noted to range from 1.13 to 65.66 × 10146 including
55/58 values >1.25 and 13/58 values >100. 1.25 is the recognized
e-value cut-off suggested in the literature likely to indicate causality [94].
We turn now to a consideration of the impact of cannabis legal
status on BC. Figure 6 shows the (A) scatterplot (jittered) of the BCI
by cannabis legal status over time, (B) the BCI by cannabis legal
status by conflated time, (C) the BCI by legal status dichotomized
as illegal versus alternative regimes and (D) a boxplot of the BCI
by dichotomized legal status over aggregated time. Significant
differences are seen between many of the lines in the scatterplots and between the notches for the Illegal—Decriminalized
statuses and between the illegal and liberal cannabis legislative
paradigms.

The results of linear regressions as suggested by Fig. 6
are shown in Table 4. Many highly significant differences
are documented. For example the decriminalized status is
noted to have a significantly higher BCI [β-est. = 3.36 (2.51,
4.21), P = 2.60 × 10−14 ] as is the liberal status [β-est. = 2.31 (1.65,
2.96), P = 9.09 × 10−12 ]. The relevant e-values are shown in
Table 3. For these two data the minimum e-values are 2.32
and 2.14.
For the BCI by dichotomized legal status the relevant BCIs
for illegal versus liberal status are 65.19 ± 0.21 and 67.50 ±
0.27/100 000, respectively (t = 6.8354, df = 654.84, P = 1.87 × 10−11 ).
The intrastate abortion rate has featured in many of the above
regression tables in final models. Supplementary Table S17 summarizes the estimates and their CIs, relative risks (RRs) and
e-values from 23 final models. As shown in Supplementary Table
S18 21 of these 23 minimum e-values are greater than the critical
1.25 threshold [94].

Discussion
Main Results
Data demonstrate for the first time a strong relationship between
cannabis exposure and BCI which is robust to adjustment for
other age, sociodemographic and selected reproductive covariates in regression models of various forms, is applicable to all
cannabinoids investigated namely THC, CBG and CBD, is maintained across space and time, is observed across all six ethnicities studied, persists after spatial and temporal lagging to at
least eight years, is evident after inverse probability weighting
and is associated with high e-values and may thus be properly said to be causal in nature. BCI is significantly higher
under medical and decriminalized cannabis legal paradigms and
under cannabis-liberal paradigms generally. To the best of our
knowledge this relationship has not been disclosed previously
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Table 3: e-Values for BCI
Parameter

MIXED EFFECTS MODELS
Cannabis alone
Cannabis
Age–cannabis interaction
Cannabis
Additive—Drugs
Cannabis
Additive—Full model
Cannabis
Interactive—Full model
Cannabis
Cigarettes:Cannabis:AUD
Interactive with ethnic THC exposure
AsianTHC
NHWhiteTHC
NHWhiteTHC:NHAfricanTHC
NHWhiteTHC:HispanicTHC
Interactive with ethnic CBD exposure
NHCaucas_CBD
NHCaucas_CBD: NHAfrican_CBD
Asian_CBD
Interactive—Cannabinoids as main effects
Cigarettes:CBG
Cigarettes:CBG:CBD
CBD
Cigarettes:CBD
PANEL REGRESSION
Additive model—Drugs only
Cannabis
Additive full model
Cannabis
Interactive full model
Cannabis
Interactive full model—2 Lags
Cigarettes:Cannabis
Interactive full model—4 Lags
Cigarettes:Cannabis
Interactive full model—6 Lags
Cannabis:AUD
Cigarettes:Cannabis
Interactive full model—8 Lags
Cigarettes:Cannabis
Cannabis:AUD

RR (CI)

e-Values

3.93 (2.99, 4.87)

2.23 (1.84, 2.69)

3.88, 3.09

2.25 (1.61, 2.89)
3.68 (2.76, 4.6)
3.23 (2.42, 4.04)
1.96 (1.38, 2.54)
1.15 (0.39, 1.9)

1.57 (1.38, 1.79)
2.11 (1.75, 2.55)
1.93 (1.64, 2.27)
1.458 (1.32, 1.67)
1.25 (1.08, 1.45)

2.53, 2.11
3.64, 2.90
3.27, 2.66
2.33, 1.97
1.81, 1.37

3.36 (2.51, 4.21)
1.63 (0.8, 2.46)

1.98 (1.67, 2.35)
1.39 (1.17, 1.65)

3.37, 2.32
2.13, 1.64

0.33 (0.13, 0.52)
0.28 (0.08, 0.47)

1.06 (1.02, 1.10)
1.05 (1.02, 1.09)

1.32, 1.18
1.28, 1.14

2.31 (1.65, 2.96)
0.18 (0.07, 0.3)

1.59 (1.39, 1.82)
1.03 (1.01, 1.06)

2.56, 2.14
1.24, 1.13

3.06 (2.15, 3.97)

2.16 (1.72, 2.72)

3.75, 2.83

8.75 (3.55, 13.96)

9.42 (2.49, 35.59)

18.33, 4.42

3.95 (2.81, 5.09)

2.89 (2.12, 3.91)

5.21, 3.67

3.08 (1.9, 4.26)

2.46 (1.75, 3.49)

4.37, 2.89

24.73 (14.98, 34.47)
1974.44 (1121.84, 2827.04)

1.67E + 03 (90.37, 31.16E + 04)
3.25E + 257 (3.33E + 146+, Infinity)

3.35E + 03, 180.25
Infinity, 6.66E + 146

3.53 (2.88, 4.18)
27.9 (21.49, 34.32)
5.94 (4.41, 7.47)
3.99 (2.77, 5.21)

3.31 (2.67, 4.15)
1.35E + 04 (1.52E + 03, 1.19E + 05)
7.57 (4.49, 12.74)
3.89 (2.57, 5.90)

6.12, 4.78
2.70E + 04, 3.05E + 03
14.61, 8.46
7.26, 4.59

65.45 (50.11, 80.79)
7.87 (5.55, 10.18)
1.32 (0.67, 1.98)

9.23E + 09 (7.45E + 06, 1.14E + 11)
11.95 (5.78, 24.75)
1.52 (5.78, 1.86)

1.85E + 09, 1.49E + 07
23.41, 11.03
2.40, 1.77

150.1 (74.14, 226.05)
25.77 (5.11, 46.44)
3.00 (0.53, 5.47)
80.19 (5.88, 154.5)

2.14E + 21 (3.77E + 10, 1.21E + 32)
4.59E + 03 (5.46, 3.87E + 06)
2.67 (1.19, 2.78)
2.49E + 11 (7.51, 8.25E + 21)

4.28E + 21, 7.56E + 10
9.19E + 03, 10.39
4.78, 1.67
4.97E + 11, 14.50

5.52 (4.18, 6.86)

1.27 (1.20, 1.36)

1.87, 1.70

8.226 (6.79, 9.66)

1.51 (1.41, 1.63)

2.40, 2.17

26.87 (22.81, 30.94)

4.23 (3.40, 5.26)

7.93, 6.26

26.69 (19.39, 33.98)

1.28 (1.18, 1.37)

1.87, 1.66

110.73 (53.78, 167.69)

2.64E + 04 (232.51, 3.01E + 06)

4.33E + 04, 464.53

1639.45 (1309.82, 1969.08)
116.37 (66.05, 166.7)

4.00E + 29 (8.99E + 23, 1.78E + 35)
2.90E + 03 (93.04, 9.07E + 03)

8.00E + 29, 1.79E + 24)
5.81E + 03, 185.58

2190 (1656.88, 2723.12)
5240 (3640.64, 6839.36)

3.59E + 63 (2.75E + 51, 4.69E + 75)
1.92E + 167 (2.73E + 130, 1.34E + 204)

7.19E + 63, 5.51E + 51
Infinity, 5.47E + 130
(continued)
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LINEAR MODELS
Cannabis_Use
Cannabinoids
THC
Cannabichromene
CBG
CBN
CBD
Legal status
Decriminalized
Medical
Time × Legal status
Year: Decriminalized
Year: Medical
Dichotomized legal status
Liberal
Year: Liberal

Estimate (CI)
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Table 3: (Continued)
Parameter

Estimate (CI)

Interactive full model—Cannabinoids as instrumental variables
Cigarettes:Cannabis
20.44 (9.5, 31.38)
Cannabis:AUD
196.03 (74.72, 317.34)
Interactive full model—Ethnic THC exposure as instrumental variables
Cigarettes:Cannabis
23.95 (8.92, 38.97)
Cannabis:AUD
245.79 (56.05, 435.54)

apparently because it has not been investigated earlier and
has also not been explored in a space–time context by prior
researchers.
Cannabis genotoxicity has previously been demonstrated in
relation to testicular and several paediatric cancers [12–15, 28, 33,
34, 36, 38–41], with genotoxicity expected to be reflected in birth
defects and in tumourigenesis rates [96]. Transgenerationally
transmissible cannabis genotoxicity has also been implied by previous studies linking prenatal cannabis exposure with congenital
birth defects including anencephalus, diaphragmatic hernia, gastroschisis and oesophageal atresia [97–100], with ventricular septal defect and Ebstein anomaly [101] and more recently with atrial
septal defect [65]. Prenatal paternal exposure has been linked
with transposition of the great vessels [102]. Indeed a classical
report from Hawaii linked prenatal cannabis exposure with 21
birth defects [103], in Canada total birth defects were recently
linked with cannabis use [104], in Australia 18 defects were linked
with cannabis exposure [105] and in Colorado a 29% rise in total
congenital defects was noted across the period of legalization
[106, 107].
One report has recently identified 42 birth defects as being significantly more common in the highest quintile of cannabis using

e-Values

281.71 (13.84, 5.73E + 03)
3.14E + 23 (9.66E + 08, 1.02E + 38)

562.93, 27.15
6.28E + 23, 1.93E + 09

729.25 (11.75, 45.24E + 04)
2.42E + 29 (5.58E + 06, 1.05E + 52)

1.45E + 03, 22.99
4.84E + 29, 1.11E + 07

1.43 (1.16, 1.77)

2.22, 1.60

1.44 (1.16, 1.77)

2.22, 1.60

1.47 (1.18, 1.83)

2.31, 1.66

2.43 (1.62, 3.65)

4.30, 2.62

1.33 (1.13, 1.58)
1.58 (1.09, 2.29)

2.01, 1.51
2.53, 1.41

4.39 (2.10, 8.90)

8.13, 3.63

1.48 (1.19, 1.85)

2.39, 1.67

7.19E + 03 (209.11, 2.47E + 05)

1.44E + 04, 417.71

244.77 (2.64, 2.26E + 04)

489.04, 4.72

166.36 (1.58, 1.74E + 04)

332.22, 2.54

185.30 (1.42, 2.42E + 04)

370.10, 2.19

273.37 (4.23, 1.76E + 04)

546.24, 7.94

64.43 (15.75, 263.63)

128.37, 30.98

52.63 (1.11, 2.49E + 03)

104.76, 1.46

4.55 (1.65, 12.52)

8.57, 2.69

US states compared to the others including arm reduction defects
[64]. Reports from several areas in France where cannabinoids
are allowed in the food chain and Germany show an unexplained
spike in congenital limb defect anomalies [108–111]. However no
such rise has been noted in nearby Switzerland where cannabinoids are not permitted to enter the food chain [108–110]. On the
basis of this recent European experience one can only conclude in
the broader genotoxic context that allowing cannabinoids to enter
to food chain can potentially lead to very serious public health
consequences indeed.
The major question at issue appears to be therefore not “Is
cannabis genotoxic?”—for that issue has clearly been settled in
the affirmative beyond reasonable doubt—but “How genotoxic is
cannabis?”—or more precisely “What are the limits of cannabis
genotoxicity in human health in this generation and in those to
follow?”.
As important as what has been shown, it seems that what
has not been shown is even more intriguing. The striking finding that the commonest human cancer is causally related to
cannabis consumption leaves open the question of which other
cancers might also be similarly implicated. It raises the important
issue that cannabis-related genotoxicity may have been seriously
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GEOSPATIAL MODELS
Cannabis alone
Cannabis
1.45 (0.61 2.29)
Additive model
Cannabis
1.45 (0.61 2.29)
Additive model without ethnicity
Cannabis
1.56 (0.69, 2.42)
Interactive model
Cigarettes:Cannabis
3.59 (1.94 5.24)
Interactive full model—Ethnic THC exposure as main effects
NHAfrican_THC:Hispanic_THC
1.14 (0.48 1.81)
NHAfrican_THC
1.8 (0.34 3.25)
Interactive full model—Ethnic CBD exposure as main effects
NHCaucas_CBD
5.63 (2.85, 8.4)
Lagged models
0 Temporal lags
Cannabis:AUD
7.26 (0.83 13.7)
1 Temporal lags
Cigarettes:Cannabis:Analgesics
313.25 (200.08 426.42)
2 Temporal lags
Cigarettes:Cannabis
21.23 (3.72, 38.73)
3 Temporal lags
Cigarettes:Cannabis
20.15482 (1.77 38.54)
4 Temporal lags
Cigarettes:Cannabis
20.84 (1.36 40.31)
1 Spatial lag
Cannabis
20.69 (5.29 36.09)
Lagging cannabinoids—THC × CBG
THC:AUD
16.69 (11.04 22.35)
1 Temporal lag cannabinoids—THC × CBG × CBD
Cigarettes:CBD
16.16 (0.39 31.93)
2 Temporal lags cannabinoids—THC × CBG × CBD
Cigarettes:CBG
6.23 (2.06 10.39)

RR (CI)
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Figure 6: Graphs of relationship of BCI to cannabis legal status. (A) Scatterplot of BCI by cannabis legal status, (B) boxplot of BCI by cannabis legal
status, (C) scatterplot of BCI by cannabis legal status dichotomized as illegal versus liberal legal paradigms and (D) boxplot of BCI by dichotomized
cannabis legal status

Table 4: Linear regression of the relationship of cannabis legal status to BCI
Parameter
Parameter

Estimate (CI)

Model
P-value

SD

Adj. R-Squared

F

Df

P-value

Legal status
lm(Cancer_Rate ∼ Legal_Status)
Decriminalized
3.36 (2.51, 4.21)
Medical
1.63 (0.8, 2.46)

2.60E − 14
0.0001

4.4734

0.0757

21.44

3746

2.51E − 13

Time × Legal status
lm(Cancer_Rate ∼ Year × Legal_Status)
Decriminalized
−651.52 (−1050.31, −252.73)
Medical
−555.49 (−947.68, −163.31)
Year: Decriminalized
0.33 (0.13, 0.52)
Year: Medical
0.28 (0.08, 0.47)

0.0014
0.0056
0.0014
0.0055

4.4233

0.0962

12.39

7742

4.62E − 15

Dichotomized legal status
lm(Cancer_Rate ∼ Dichotomized legal_status)
Liberal
2.31 (1.65, 2.96)

9.09E − 12

4.5133

0.0591

48.03

1748

9.09E − 12

Time × Dichotomized legal status
lm(Cancer_Rate ∼ Year × Dichotomized legal_status)
Liberal
−436.94 (−746.96, −126.92)
Year: Liberal
0.18 (0.07, 0.3)

0.0059
0.0018

4.4887

0.0693

19.6

3746

3.08E − 12

underestimated in our culture generally in the consciousness of
the public health community, the medical profession, government and health regulators and the general community alike.
Indeed a recent analysis of European data confirms that cannabis
exposure is similarly related to several common cancers when

considered in a space–time paradigm and by applying the tools
of causal inference (three manuscripts in press).
AUD (formerly known as alcohol dependence) is featured in
some final geospatial models but it was not independently significant or prominent in the results in the same way as cannabis,
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Pathophysiological Mechanisms
Endocrine Disruption
Various cannabinoids have been shown to interact with the
endocrine system and have been noted to act as endocrine disruptors in ovaries, testes and placenta [126–130], and cannabinoids
are also involved in breast pathophysiology [11, 131] and are normally excreted in breast milk [132, 133]. Endocrine disruption has
been noted to be a powerful negative impactor of human health
[134, 135]. Agonists at the Type 1 and 2 cannabinoid receptors
(CB1R and CB2R) are known to interfere with the hypothalamicpituitary-gonadal axis in human females [11], hypothalamicpituitary-adrenal axis [136–138], with insulin [139, 140] and other
hormones and to stimulate human prolactin levels [141–143].
Various cannabinoid concentrations have been noted both to
stimulate [131] and inhibit [144–146] the growth of BC cells in
culture.
It was recently noted that many hormones cause rapid and
widespread re-arrangement of the genome through epigenomic
mechanisms [147]. This makes sense particularly for the many
steroid and sex hormones which are lipophilic and directly engage
nuclear hormone receptors [148].

For example the cannabinoid THC has long been known to test
positive in the micronucleus assay and micronuclei are known
to be a major engine for chromothriptic events [149, 164]; THC,
CBD and cannabinol (CBN) have been implicated in chromosomal translocation events [165]; THC and CBG have been implicated in congenital heart defects incidence across USA [65, 101];
cannabidivarin and CBD have been shown to test positive in the
comet assay for DNA breaks and have been shown to cause the
oxidation of all four DNA bases [166]; THC largely modulates DNA
methylation at CpG islands of sperm DNA with neurological and
functional impacts for subsequent generations [150, 151, 154–156,
158]; and cannabis use has been linked with the chromosomal trisomy Downs syndrome in Canada, Australia, Colorado, Hawaii
and the USA [103–105, 167, 168]. Cannabinoids are also highly
toxic to mitochondria [169–177] which impact genetic and epigenetic processes directly through ATP and epigenetic substrate
supply [107, 178, 179] and also indirectly through mitonuclear balance pathways [178, 179]. Hence multiple pathways exist by which
cannabis use could potentially impact BCI.
The subjects of cannabinoid genotoxicity and epigenotoxicity
are large and complex and have been reviewed in detail elsewhere
[40, 64, 65, 105, 107, 149–158, 166, 168, 180]. In this regard a recent
single tumour cell DNA sequencing study showing that haematological malignancies can arise due to clonal sweeps in the setting
of specific genotoxic stressors is of particular interest and may
also apply to solid organ carcinogenesis [181].

Transgenerational Effects
Epimutations of the DNA methylome noted in the sperm after
cannabis use in rats and humans include pathways in cancer,
hippo pathways and mitogen-activated protein kinase pathways
which are all involved in cancer [156, 182]. Significant overlap has also been found with autism genes, genes involved in
neural, cerebral, cognitive and brain development and learning,
glutamatergic synapse formation and cardiogenesis [156, 182].
This important finding implies transgenerational epigenetic
inheritance in humans and confirmed the significance of such
findings in rodents on reproductive outcomes.
Reproductive cancers identified as cannabis-associated by a
recent review of European data include testicular cancers including both non-seminoma germ cell and seminoma and also its
homologue in the female the dysgerminoma of the ovary together
with breast, vulvar and vaginal cancers [183].
In a recent review of European congenital anomalies genital
disorders including hypospadias and the genetic syndromes trisomies 21, 18 and 13 (Syndromes of Down, Edwards and Patau)
along with chromosomal disorders, genetic and microdeletion
syndromes, and Turner (female XO) and Klinefelter (male XXY)
syndromes were found to be cannabis-related [183].
It is important to note that if one adds together the length
of all the chromosomes implicated by these clinical syndromes
(13, 18, 21, 22 and X) with those implicated from cannabis-related
tumourigenesis (testicular cancer and ALL [43, 48], Chromosomes
12 and 19) one arrives at a surprising 585 MB of the 3000 MB
or 19.5%, of human genome directly impacted by cannabinoid
genotoxicity.

Genotoxicity and Epigenotoxicity
Several cannabinoids also act at clinically relevant doses by multiple genotoxic mechanisms on genes, the bases of DNA, chromosomes and the epigenome [64, 149–158]. Cannabis tars contain most of the same carcinogens as tobacco tars [159–163].

Accelerated Ageing Including Potentially Gamete Ageing
It was shown several years ago that cannabis consumption is associated with an increase in cardiovascular age and therefore the
biological age of the human organism [185].
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the cannabinoids or abortion. The index of alcohol consumption
used in the present analysis was AUD which is a different metric to alcohol consumption per se. The AUD measure was used
as we wished to look at the possibly genotoxic effects of alcohol
which are likely more linked with individuals dosing at higher levels. Importantly it has been noted that foetal alcohol syndrome
is mediated epigenomically via the cannabinoid type 1 receptor
(CB1R) [112–119].
While there are many modes of consuming cannabis, some
common ones involve mixing cannabis with tobacco, and consuming as either a self-rolled cigarette or cigar, or smoking in a
pipe. Accordingly, this may cause confounding when assessing
the association of cannabis use with selected morbidities. However, despite laboratory based mechanistic evidence that compounds found in tobacco may induce BC [120, 121], data from
a number of systematic epidemiological reviews have identified
no overall association [122, 123]. Notwithstanding controversy
still continues with a number of recent cohort studies indicating an increased risk of BCI among women with a significant
history of tobacco use, or who commenced use at a young age
[124, 125]. Unequivocal results likely reflect tobacco’s negative or
lesser role as a contributing antecedent to BC compared to other
more robust known aetiological factors. It is therefore unlikely
that co-use of tobacco with cannabis impacts largely on study
findings.
Although the intrastate abortion rate was not a primary focus
of the present analysis it was included as a covariate. It is noted
that abortion persisted as an independently significant term in
many final space–time models and so it appears to be an independent BCI covariate in this space–time and causal inference
analysis. However since much of these data are temporally and
spatially kriged this conclusion should be regarded as provisional
at this point.

Cannabinoid and other drug risk factors for female breast cancer

Generalizability
We feel that the present results are widely generalizable for several reasons. The present analysis is based on a large populationlevel data set and has many narrow CIs and highly significant
P-values. This analysis takes into account many covariates which
have been previously shown to be related to BCI. Many very high
e-values imply that the inclusion of further covariates is unlikely
to disturb the main conclusions. Moreover, the results explain various lifestyle factors which may be driving a global increase in
the BCI beyond those which are have been identified to date. The

strongly positive results from the causal inference analyses indicate that the relationship fulfills the criteria for causality and so is
likely to apply in all nations where data of adequate quality exists.

Strengths and Limitations
This report has a number of strengths and weaknesses. Its
strengths include the use of a national census database for BC
and socio-economic and sociodemographic variables, the use of
a nationally representative sample with high response rates for
drug use data, the confirmation of the main results by a variety of regression techniques, the use of multivariable regression
across both space and time simultaneously, the use of spatially
and temporally lagged models, the use of additive and interactive models, the calculation of high precision P-values down to
P < 10−320 , the use of multiple covariates across different domains,
the use of multiple graphs and map-graphs to display the results
and direct the analysis, the use of different forms of correlogram, the use of the techniques of causal inference particularly
inverse probability weighting and e-values and the use of robust
regression techniques. Weaknesses include the unavailability of
some component data sets for HRT, hormonal contraception and
abortions, the unavailability of data relating to other reproductive factors such as age of first childbearing, age of menarche, age
of menopause and duration of breastfeeding and the limitation
of the present analysis to state-level data. However, the generally high e-values indicate that the inclusion of further covariates is unlikely to change the principal conclusions substantially.
Clearly subsequent analyses in this field need to be performed by
those who have access to more comprehensive data sets and can
perform analyses at higher geospatial resolution.
A further extension of the present work is the combining of
causal inference techniques into spatial models. In R-packages
such as the complex survey package it is possible to assign the
error term as a product of several lists of weights [81]. This facility
is not presently implemented in geospatial modelling techniques
in R. However such an implementation within geospatial methods would represent a major addition to the field by ushering
in a first-in-class causal geospatial method which has not previously been deployed. Such an implementation would therefore
powerfully enhance both formal quantitative causal inference as
well as geospatial inferential techniques. The option of the use
of instrumental variables within spatial methods would also be
analytically and inferentially of both considerable interest and
utility.
The implications of this finding are far reaching. As noted in
the Background section of the present paper BC is the commonest
cancer of all. Cannabis is presently enjoying widespread popularity deriving from its celebrated and indeed unique status in the
popular culture and the common perception of its apparent safety
as a “soft drug.” In many US states foods which are marketed as
low in THC are represented as posing no threat to human health.
The dramatic results presented above applying to CBG and CBD in
particular demonstrate that in relation to BC this is quite untrue
and indeed in terms of the downstream public health implications
constitutes a very dangerous practice.
This is particularly applicable to “industrial hemp” which is
said to be low in THC, but likely higher in other cannabinoids. The
US Farm Act is believed to have allowed hemp products to be used
as cattle fodder, implying that cannabinoids can now enter the
food chain in meat, milk and dairy products. If used in chicken
feed, this will extend also to eggs.
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It has also been shown that patients who consume tobacco,
opioids and cannabis have a dramatic truncation of the female
reproductive lifespan with a 58% reduction in their fertile period
as measured by the key metric the Follicle Stimulating Hormone (FSH)/Luteinizing Hormone (LH) ratio which inverts premenopausally and is a sensitive biomarker of the perimenopause
[185]. These investigators found a reduction in the age of ratio
inversion from 46.2 years to 28.1 years. It was also recently demonstrated that smoking 20 cigarettes daily reduces the age of natural menopause by only one year [186]. Moreover, these investigators also found that ovarian ageing is invariably caused
by activation of the DNA damage response (DDR). This further implies that the dramatic acceleration of premature ovarian failure by combined opioid–cannabinoid use is induced
by a marked increase in ovarian DDR to damaged germline
DNA.
Numerous deleterious effects of cannabinoids on sperm development have been described including DNA fragmentation, disruption of protamine–histone substitution and so DNA packing,
DNA nicking by nuclear transition protein 2 (tnp2), protection of
DNA and nuclear size and a reduced concentration of sperm in the
seminiferous ducts [177, 187, 188]. Cannabinoids are also found in
the midcycle oviduct fluid and in the fluid of the Graafian follicle
[177, 187, 188].
Together with the finding that nuclear architecture is
exquisitely sensitive to hormonal signals [147] this demonstrates
that reproductive tissues can be powerfully impacted by environmental stimuli. A dramatic effect of cannabis on oocyte cell
division was also shown by classical investigators including the
documentation of a 20% cell loss with just a single oocyte cell
division and severe derangement of nuclear architecture including nuclear blebs and bridges and chromosomal nondisjunctions
[189]. The above noted parallelism between the well-established
cannabis-testicular non-seminomatous germ cell tumours
[12–15, 18–21] and the newly described link between cannabis
consumption and the homologous female tumour the ovarian
dysgerminoma is particularly germane in regard to gonadal and
germ cell ageing (manuscript submitted).
These more recent findings collectively imply accelerated ageing of the germ cells themselves and thus the gametes derived
from them as their downstream progeny. In terms of breast carcinogenesis one can conjecture that it may be shown in time that
these factors may be relevant to either the oncogenic incubation
phase in the adult or in pre-conceptual developmental influences.
It is important to observe that whilst malignant and congenital anomaly outcomes are relatively rare as cannabinoids
increasingly enter the food chain [190], population-wide genomic
and epigenomic ageing can be expected to become universal
as implied by elegant, sophisticated and powerful research on
epigenomic ageing from Harvard Medical School [191].
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In states such as Colorado where cannabis is completely legalized CBD cookies, sauces, jams and sweets are widely marketed apparently as they are non-psychoactive and said to be
benign. Both claims are likely erroneous. CBD in fact does bind to
CB1R receptors at high doses [192–196] which can presumably be
achieved under high level dosing such as may commonly be seen
under cannabis-legal paradigms, and CBD has mental and genotoxic effects which can be reversed by application of canonical
CB1R antagonists [96].
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